# Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Source: https://onco.cc/trials/nct05838729/  
OnCo record `nct05838729` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of RiMO-301 in advanced solid tumours, run by Coordination Pharmaceuticals, Inc., now recruiting.

## Summary

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer is a phase 1/2 interventional study registered as NCT05838729 by Coordination Pharmaceuticals, Inc., with 16 participants planned, started 2023-04-03 and due to reach its primary completion in 2026-09. Interventions recorded: RiMO-301.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05838729
- Phase: 1/2
- Setting: Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer
- Sponsor: Coordination Pharmaceuticals, Inc.
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT05838729: https://clinicaltrials.gov/study/NCT05838729

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05838729.json